title: Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction.
abstract: Sivelestat sodium hydrate (sivelestat) is a selective inhibitor of polymorphonuclear leukocyte elastase (PMN-E). We administered sivelestat to patients with septic acute lung injury (ALI) to examine its usefulness. The primary endpoints in the study were the duration of artificial ventilation and pulmonary oxygenation ability, and the secondary endpoints were mortality and the concentrations of PMN-E, SP-D, TNF-alpha and IL-8 in blood. In the sivelestat group, the duration of artificial ventilation, pulmonary oxygenation ability, and the blood PMN-E, SP-D, TNF-alpha and IL-8 concentrations decreased significantly. Administration of sivelestat was found to reduce alveolar dysfunction and improve respiratory function, and it was suggested that early administration might be useful.
authors.affiliation: Department of Critical Care Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka 020-8505, Japan. sendo@iwate-med.ac.jp
authors.forename: Shigeatsu
authors.initials: S
authors.lastname: Endo
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sato
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Yaegashi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kojika
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Yamada
authors.forename: Yuki
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Toshihide
authors.initials: T
authors.lastname: Nakadate
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Aoki
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Inoue
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors / Q000097:blood; D007962:Leukocytes / Q000187:drug effects*; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D011652:Pulmonary Circulation / Q000187:drug effects*; D037663:Pulmonary Surfactant-Associated Protein D / Q000097:blood; D012121:Respiration, Artificial / Q000706:statistics & numerical data; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D016019:Survival Analysis; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D016209:Interleukin-8; D037663:Pulmonary Surfactant-Associated Protein D; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; C069195:sivelestat; D019272:Leukocyte Elastase; D010100:Oxygen; D005998:Glycine